Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
1 clinical trials · Condition
◉ Watch Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
| Record | Firm | Date |
|---|---|---|
| A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes (NCT00910858) | Celgene Corporation | 2005-01-01 |
Track Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS) automatically
Every clearance here is in the API, with alerts when new ones post.